Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Evaluating rapamycin treatment in Alzheimer's disease using positron emission tomography (ERAP)
2023-000127-36Phase 2Completed
- Sponsor
- Karolinska Institutet
- Start
- Jan 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2 trial of sirolimus in Alzheimer's disease (AD) and Mild Cognitive Impairment (MCI), sponsored by Karolinska Institutet. Primary endpoint: Change-from-baseline 18F-FDG cerebral uptake. Started Jan 2023; status: completed.
02
Drugs
sirolimus
03
Conditions
Alzheimer's disease (AD)Mild Cognitive Impairment (MCI)
Beyond the preview
Go deeper on 2023-000127-36.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-000127-36.